With cardiovascular disease continuing to present a significant health concern, EPR reflects on recent development efforts and drug approvals in the space with comment from Dr Douglas Clark of Boehringer Ingelheim.
The U.S. FDA on Thursday blessed Lilly and Boehringer’s Jardiance with a label expansion to curb the risk of cardiovascular death and hospitalization for heart failure in adults. The move comes after the partners in November sent off an FDA application for the med to treat adults with heart failure independent of left ventricular ejection fraction.
NetworkNewsWire: Hypertension: The Silent Killer Making Loud Noise for Investors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Hypertension: The Silent Killer Making Loud Noise for Investors prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.